According to a study published in the New England Journal of Medicine, Vemurafenib (Zelboraf) speeds the growth of squamous cell carcinoma. HealthDay explained that “roughly one-quarter of patients who take the medication develop a troublesome side effect: secondary skin cancers called squamous cell carcinomas.”
Posted in Malignant melanoma, Uncategorized